Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 1 of 7
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Bristol-Myers Squibb
NCT07379827
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
NCT07114874
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals
NCT05184335
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
Massachusetts General Hospital
NCT04296604
CLOZAPINE Response in Biotype-1
University of Texas Southwestern Medical Center
NCT04580134
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT06894212
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies
NCT06229210
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals
NCT06961968
Enhanced Coordinated Specialty Care for Early Psychosis
Mclean Hospital
NCT06071858
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Gedeon Richter
NCT03817502
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
Beth Israel Deaconess Medical Center
NCT06740383
Taking Action for College Students
Temple University
NCT06700902
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
MapLight Therapeutics
NCT07038876
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Bristol-Myers Squibb
NCT07101094
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
NCT07105098
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
NCT06963034
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
New York State Psychiatric Institute
NCT05208190
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics
NCT05304767
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
AbbVie
NCT07145918
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes
NCT05303064
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
Yale University
NCT06058702
Song-making In a Group (SING)
Yale University
NCT05929352
Cerebellar Stimulation and Cognitive Control
Krystal Parker, PhD
NCT03217110
Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation
Fabio Ferrarelli
NCT05956951
CBT-CP for Veterans With SMI
VA Office of Research and Development
NCT06758414
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
Brigham and Women's Hospital
NCT06376734
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
NCT07288567
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
University of California, San Francisco
NCT04807530
Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia
University of California, Davis
NCT04267003
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
Vishwajit Nimgaonkar, MD PhD
NCT03794076
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
NCT07467993
Neuronal Effects of Exercise in Schizophrenia
University of Colorado, Denver
NCT02455193
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics
NCT05025605
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
The University of Texas Health Science Center, Houston
NCT06345963
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)
The University of Texas Health Science Center, Houston
NCT06961916
Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness
Massachusetts General Hospital
NCT04940663
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
VA Office of Research and Development
NCT05157620
Anticholinergic Deprescription in Schizophrenia
Deepak K. Sarpal, M.D.
NCT06562608
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Boston VA Research Institute
NCT05299749
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
University of California, Los Angeles
NCT05890183
iTBS to Enhance Social Cognition in People With Psychosis
Northwell Health
NCT06118268
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Yale University
NCT01730781
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
NCT05648591
Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility
Kai Hwang
NCT07217652
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
Vanderbilt University Medical Center
NCT07196462
Cerebellar Modulation of Cognition in Psychosis
Mclean Hospital
NCT06107764
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
University of Pittsburgh
NCT04143126
Study of ALTO-101 in Patients With Schizophrenia
Alto Neuroscience
NCT06502964
Effectiveness of Motivation Skills Training (MST)
Columbia University
NCT05805397
Enhancing Rehabilitation for Veterans With Serious Mental Illness
VA Office of Research and Development
NCT06586164
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.